Highlights Newsletter 1
This newsletter presents you the following key sessions:
3. Glofitamab plus gemcitabine and oxaliplatin shows survival benefit in R/R DLBCL
4. Frontline blinatumomab active in Down Syndrome B-cell acute lymphoblastic leukaemia